|Bid||22.80 x 800|
|Ask||25.09 x 1100|
|Day's Range||24.52 - 25.11|
|52 Week Range||23.29 - 42.13|
|Beta (5Y Monthly)||0.94|
|PE Ratio (TTM)||15.79|
|Forward Dividend & Yield||0.71 (2.82%)|
|Ex-Dividend Date||May 13, 2022|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for FMS
The U.S. Supreme Court on Tuesday rejected dialysis provider DaVita Inc's claims that an Ohio hospital's employee health plan discriminates against patients with end-stage kidney disease by reimbursing them at low rates in hopes they would switch to Medicare. In a 7-2 decision https://fingfx.thomsonreuters.com/gfx/legaldocs/byvrjaqorve/06212022davita.pdf authored by conservative Justice Brett Kavanaugh, the court ruled that Marietta Memorial Hospital's employee health plan did not violate federal law by limiting benefits for outpatient dialysis because it did so without regard to whether patients had end-stage renal disease.
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Fresenius Medical's (FMS) first-quarter earnings benefit from strong performance across all the geographic regions and segments.